Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML

Name: Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML
Published: 2026
License: Public Domain

The University of Hong Kong · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

ph+ acute lymphoblastic leukemia (ph+all), blastic transformation of chronic myeloid leukemia, philadelphia chromosome-positive b-cell acute lymphoblastic leukemia (ph+ b-all), haematopoietic stem cell transplant, allogeneic, ph+ b-all, cml-bp, asciminib, asciminib add-on, allogeneic hsct maintenance, asciminib with imatinib, asciminib with nilotinib, asciminib with dasatinib

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 827014
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.